Literature DB >> 16709843

Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.

Elizabeth A Jacobsen1, Olga Ananieva, Matthew L Brown, Yung Chang.   

Abstract

The nonreceptor tyrosine kinase, encoded by the v-Abl oncogene of Abelson murine leukemia virus induces transformation of progenitor B cells. The v-Abl oncogene promotes cell cycle progression and inhibits pre-B cell differentiation. The temperature-sensitive form of Abelson murine leukemia virus offers a reversible model to study the role of v-Abl in regulating growth and differentiation. Inactivation of v-Abl elevates p27 and Foxo3a levels and activates NF-kappaB/Rel, which leads to G1 arrest and induction of Ig L chain gene rearrangement, respectively. In turn, v-Abl reactivation reduces p27 and Foxo3a levels, thus permitting G1-arrested cells to reenter the cell cycle. However, the cell lines derived from SCID mice that are defective in the catalytic subunit of DNA-dependent protein kinase retain elevated levels of p27 and Foxo3a proteins despite reactivation of v-Abl. Consequently, these cells are locked in the G1 phase for an extended period of time. The few cells that manage to bypass the G1 arrest become tumorigenic and fail to undergo pre-B cell differentiation induced by v-Abl inactivation. Deregulation of p27, Foxo3a, c-myc, and NF-kappaB/Rel was found to be associated with the malignant transformation of SCID temperature-sensitive form of Abelson murine leukemia virus pre-B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709843     DOI: 10.4049/jimmunol.176.11.6831

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Int J Mol Med       Date:  2007-02       Impact factor: 4.101

Review 2.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2007-11       Impact factor: 2.303

Review 3.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

4.  Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation.

Authors:  Lobke Snoeks; Christopher R Weber; Kaarin Wasland; Jerrold R Turner; Charles Vainder; Wentao Qi; Suzana D Savkovic
Journal:  Lab Invest       Date:  2009-07-27       Impact factor: 5.662

Review 5.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

6.  Diabetes mellitus: channeling care through cellular discovery.

Authors:  Kenneth Maiese; Yan Chen Shang; Zhao Zhong Chong; Jinling Hou
Journal:  Curr Neurovasc Res       Date:  2010-02       Impact factor: 1.990

Review 7.  A "FOXO" in sight: targeting Foxo proteins from conception to cancer.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Med Res Rev       Date:  2009-05       Impact factor: 12.944

Review 8.  Erythropoietin and oxidative stress.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Curr Neurovasc Res       Date:  2008-05       Impact factor: 1.990

Review 9.  OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang
Journal:  Trends Mol Med       Date:  2008-04-09       Impact factor: 11.951

Review 10.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.